Khorram O, Garthwaite M, Grosen E, Golos T
Department of Obstetrics and Gynecology, University of Wisconsin, Madison, Wisconsin, USA.
Fertil Steril. 2001 Jan;75(1):174-9. doi: 10.1016/s0015-0282(00)01658-7.
To determine uterine and ovarian expression of growth hormone-releasing hormone (GHRH) messenger RNA (mRNA) in benign and pathologic gynecologic states.
Case-control study.
Tertiary-care academic department.
PATIENT(S): Women undergoing hysterectomy for benign or malignant gynecologic conditions.
INTERVENTION(S): Ovarian and uterine tissue was obtained for measurement of GHRH mRNA levels by reverse transcription polymerase chain reaction.
MAIN OUTCOME MEASURE(S): Levels of GHRH mRNA in normal tissues were compared with those in tissues with pathologic abnormalities.
RESULT(S): Growth hormone-releasing hormone mRNA was detectable in the ovary, endometrium, myometrium, fallopian tubes, and placenta. Levels of GHRH mRNA were significantly increased in secretory endometrium compared with proliferative endometrium. Hormone replacement therapy did not affect endometrial GHRH mRNA levels. Uterine myomas expressed similar levels of GHRH mRNA as normal myometrium. No changes in endometrial GHRH mRNA were detected in endometrial cancers compared with normal endometrium or myometrium obtained from the same patient; however, these levels were higher than those in noncancerous myometrial tissue obtained from other patients with benign gynecologic disease. In ovarian tissue, no differences in GHRH mRNA were found between premenopausal and postmenopausal women. Ovarian GHRH mRNA was significantly decreased in endometriotic cysts, whereas significantly greater GHRH expression occurred in ovarian cancer compared with normal ovarian tissue.
CONCLUSION(S): Endometrial and ovarian GHRH gene transcription are altered in selective physiologic and pathologic states and are influenced by such factors as ovarian hormones. Because it is a growth factor, GHRH may promote endometrial proliferation and may be involved in the pathogenesis of ovarian and endometrial cancer and endometriosis.
确定生长激素释放激素(GHRH)信使核糖核酸(mRNA)在良性和病理性妇科状态下子宫和卵巢中的表达情况。
病例对照研究。
三级医疗学术科室。
因良性或恶性妇科疾病接受子宫切除术的女性。
获取卵巢和子宫组织,通过逆转录聚合酶链反应测量GHRH mRNA水平。
将正常组织中GHRH mRNA水平与有病理异常的组织中的水平进行比较。
在卵巢、子宫内膜、子宫肌层、输卵管和胎盘中可检测到生长激素释放激素mRNA。与增殖期子宫内膜相比,分泌期子宫内膜中GHRH mRNA水平显著升高。激素替代疗法不影响子宫内膜GHRH mRNA水平。子宫肌瘤表达的GHRH mRNA水平与正常子宫肌层相似。与同一患者的正常子宫内膜或子宫肌层相比,子宫内膜癌中未检测到子宫内膜GHRH mRNA的变化;然而,这些水平高于从其他患有良性妇科疾病的患者获得的非癌性子宫肌层组织中的水平。在卵巢组织中,绝经前和绝经后女性的GHRH mRNA没有差异。子宫内膜异位囊肿中卵巢GHRH mRNA显著降低,而与正常卵巢组织相比,卵巢癌中GHRH表达显著增加。
子宫内膜和卵巢GHRH基因转录在选择性生理和病理状态下发生改变,并受卵巢激素等因素影响。由于GHRH是一种生长因子,它可能促进子宫内膜增殖,并可能参与卵巢癌、子宫内膜癌和子宫内膜异位症的发病机制。